The cost of drug development: A systematic review

Health Policy

Volumn 100, Issue 1, 2011, Pages 4-17

  Morgan, Steve ^a   Grootendorst, Paul ^b   Lexchin, Joel ^c   Cunningham, Colleen ^a   Greyson, Devon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YORK UNIVERSITY   (Canada)

Author keywords

Drug development; Innovation; Pharmaceuticals; Research and development; Systematic review

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT;

ACCOUNTING; CAPITAL; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; INVESTMENT; MEDICAL AUDIT; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

CAPITAL FINANCING; COSTS AND COST ANALYSIS; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; MODELS, ECONOMETRIC;

EID: 79952587191     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.12.002     Document Type: Review

References (22)

1. Hansen R.W., Chien R.I. The pharmaceutical development process: estimates of development costs and times and the effect of proposed regulatory changes. Issues in pharmaceutical economics 1979, 151-191. Lexington Books, Lexington, MA.
2. Adams C.P., Brantner V.V. Spending on new drug development. Health Economics 2010, 19(2):130-141.
3. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 2010, 9:203-214.
4. Wiggins S.N. The cost of developing a new drug 1987, Pharmaceutical Manufacturers Association, Washington, DC.
5. Dimasi J.A. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 1991, 10:107-142.
6. Dimasi J.A. Research and development costs for new drugs by therapeutic category: a study of the U.S Pharmaceutical Industry. PharmacoEconomics 1995, 7:152-169.
7. Dimasi J.A., Grabowski H.G., Vernon J. R&D costs innovative output and firm size in the pharmaceutical industry. International Journal of the Economics of Business 1995, 2:201-219.
8. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003, 22(2):151.
9. DiMasi J.A., Grabowski H.G., Vernon J. R&D costs and returns by therapeutic category. Drug Information Journal 2004, 38(3):211-223.
10. DiMasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: is biotech different?. Managerial and Decision Economics 2007, 28(4-5):469-479.
11. Young B., Surrusco M. Rx R&D myths: the case against the drug industry's R&D " Scare Card" 2001, Public Citizen, Washington, DC.
12. The Global Alliance for TB Drug Development. Economics of TB drug development. Report; 2001.
13. Adams C.P., Brantner V.V. Estimating the cost of new drug development: is it really $802 million?. Health Affairs (Millwood) 2006, 25:420-428.
14. Grabowski H.G., Vernon J.M. Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics 1994, 13(4):383-406.
15. Danzon P.M., Epstein A., Nicholson S. Mergers and acquisitions in the pharmaceutical and biotech industries: the Wharton School 2004, University of Pennsylvania, May.
16. DiMasi J.A., Hansen R.W., Grabowski H.G. Extraordinary claims require extraordinary evidence. Journal of Health Economics 2005, 24(5):1034-1044.
17. DiMasi J.A. Rising research and development costs for new drugs in a cost containment environment. PharmacoEconomics 1992, 1(Suppl. 1):13-20.
18. Love J. Evidence regarding research and development investments in innovative and non-innovative medicines 2003, Consumer Project on Technology, Washington, DC.
19. Light D.W., Warburton R.N. Extraordinary claims require extraordinary evidence. Journal of Health Economics 2005, 24(5):1030-1033.
20. United States of America New drug development: science, business, regulatory and intellectual property issues cited as hampering drug development efforts 2006 November, Government Accountability Office, Washington.
21. U.S. Congress OoTA. Pharmaceutical R&D: costs, risks and rewards. Report. Washington, DC: Government Printing Office; 1993.
22. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the U.S. Pharmaceutical Industry. PharmacoEconomics 1995, 7(2):152-169.